Elixir Medical has begun patient enrolment in an international pivotal clinical study to assess the safety and efficacy of its DESolve novolimus-eluting bioresorbable coronary scaffold system for treating coronary blockages.

The DESolve system features a poly-L-lactide-based polymer scaffold to support the coronary artery while delivering the novolimus.

The multicentre, prospective DESolve Nx study will enrol 120 patients at up to 15 centres in Germany, Belgium, Poland, Brazil and New Zealand.

The primary safety endpoint will be cardiac death, target vessel myocardial infarction and clinically-indicated target vessel revascularisation, and the angiographic endpoint includes in-stent late lumen loss at six months for all patients as assessed by quantitative coronary angiography.

Elixir Medical CEO Motasim Sirhan said the company will provide physicians with multiple sizes of the DESolve System to address broad patient population needs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.